The estimated Net Worth of Jay Shepard is at least $1.35 Milhão dollars as of 15 May 2024. Mr. Shepard owns over 2,166 units of Esperion Therapeutics stock worth over $12,253 and over the last 11 years he sold ESPR stock worth over $1,027,600. In addition, he makes $308,387 as Independent Director at Esperion Therapeutics.
Jay has made over 21 trades of the Esperion Therapeutics stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 2,166 units of ESPR stock worth $3,769 on 15 May 2024.
The largest trade he's ever made was selling 24,211 units of Esperion Therapeutics stock on 31 January 2017 worth over $333,385. On average, Jay trades about 3,526 units every 52 days since 2013. As of 15 May 2024 he still owns at least 7,042 units of Esperion Therapeutics stock.
You can see the complete history of Mr. Shepard stock trades at the bottom of the page.
Jay P. Shepard serves as Independent Director of the Company. He was appointed to our Board in May 2018. Mr. Shepard has served as the President and Chief Executive Officer of Versartis, Inc. since May 2015, and previously served as Executive Chairman of the Versartis, Inc. Board of Directors from December 2013 to 2015. Versartis merged with Aravive Biologics in 2018 and Mr. Shepard continues to serve as Chief Executive Officer. From 2008 to 2015, Mr. Shepard was the Executive Partner at Sofinnova Ventures. Previously, he was the President and Chief Executive Officer of NextWave Pharmaceuticals (acquired by Pfizer), President and Chief Executive Officer of Ilypsa (acquired by Amgen), interim President and Chief Executive Officer of Relypsa (Ilypsa's spin-out company, which was acquired by Galencia), and Vice President of Commercial Operations at Telik and Oncology Business Unit Head of Alza Pharmaceuticals (Alza was acquired by Johnson & Johnson). He has over 35 years of experience in the pharmaceutical, biotechnology and drug delivery arenas, and has participated in or led over 16 product launches by preparing markets and establishing sales and marketing operations. Mr. Shepard also serves as a board member of Aravive, Inc., the Christopher & Dana Reeve Foundation, and the Santa Clara University Entrepreneurial School. Mr. Shepard holds a B.S. in business administration from the University of Arizona.
As the Independent Director of Esperion Therapeutics, the total compensation of Jay Shepard at Esperion Therapeutics is $308,387. There are 8 executives at Esperion Therapeutics getting paid more, with Timothy Mayleben having the highest compensation of $1,080,850.
Jay Shepard is 62, he's been the Independent Director of Esperion Therapeutics since 2018. There are 3 older and 12 younger executives at Esperion Therapeutics. The oldest executive at Esperion Therapeutics Inc. is Antonio Gotto, 84, who is the Independent Director.
Jay's mailing address filed with the SEC is C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON, MA, 02110.
Over the last 11 years, insiders at Esperion Therapeutics have traded over $197,978,412 worth of Esperion Therapeutics stock and bought 6,755,593 units worth $134,445,709 . The most active insiders traders include Patrick G Enright, Target N Vbb Biotech Ag Bio..., eNicole Vitullo. On average, Esperion Therapeutics executives and independent directors trade stock every 33 days with the average trade being worth of $145,621. The most recent stock trade was executed by Eric Warren on 19 August 2024, trading 211 units of ESPR stock currently worth $411.
esperion therapeutics, inc. is a pharmaceutical company focused on developing and commercializing first-in-class, oral, ldl-c lowering therapies for the treatment of patients with hypercholesterolemia. etc-1002, the company's lead product candidate, is an inhibitor of atp citrate lyase, a well-characterized enzyme on the cholesterol biosynthesis pathway; the same pathway that includes hmg-coa reductase, the enzyme target of statins. the company has successfully completed its phase 1 and phase 2 development programs for etc-1002, and plans to initiate its etc-1002 phase 3 development program by the end of 2015. for more information, please visit www.esperion.com.
Esperion Therapeutics executives and other stock owners filed with the SEC include: